Company news
Starpharma Holdings Limited (ASX:SPL) news
Starpharma Holdings Limited news releases on 6ix. Latest, Feb 28, 2023: Interim Report and Half-Year Financial Results
Press releases — page 2
Interim Report and Half-Year Financial Results
February 27, 2023
Quarterly Activities Report & Appendix 4C
January 29, 2023
Response to ASX Query Letters
January 12, 2023
Starpharma receives $7.1M R&D tax incentive refund
December 22, 2022
VIRALEZE Nasal Spray Registered in Indonesia
December 14, 2022
Positive AZD0466 clinical data presented by AstraZeneca
December 13, 2022
AGM Chairman address and CEO presentation
November 29, 2022
VIRALEZE distribution agreement for Hong Kong and Macau
October 20, 2022
New clinical data for DEP cabazitaxel in prostate cancer
September 11, 2022
S&P DJI Announces September 2022 Quarterly Rebalance
September 2, 2022
Starpharma annual report and full year financial results
August 25, 2022
Starpharma signs new DEP agreement with MSD
August 10, 2022
Starpharma : Quarterly Activities Report & Appendix 4C
July 28, 2022
VIRALEZE Protects Against Omicron in Viral Challenge Model
July 20, 2022
VIRALEZE relaunched by LloydsPharmacy in the UK
June 30, 2022
SPL signs expanded DEP research agreement with US Biopharma
June 26, 2022
SPL7013 in VIRALEZE virucidal against influenza A and B
May 17, 2022
Quarterly Cashflow and Activities Report
April 29, 2022
Starpharma : Quarterly Cashflow and Activities Report
April 28, 2022
VIRALEZE to relaunch in the UK
March 31, 2022
Starpharma : Application for quotation of securities - SPL
March 17, 2022
SPL7013 in VIRALEZE virucidal against Omicron
March 1, 2022
Starpharma : Interim Report and Half-Year Financial Results
February 20, 2022
VIRALEZE sales and distribution in Saudi Arabia and GCC
February 2, 2022
Starpharma - Quarterly Cashflow and Activities Report
January 31, 2022
Starpharma receives $7.7M R&D tax incentive refund
January 19, 2022
VIRALEZE successfully launched in Vietnam
December 13, 2021
Starpharma signs DEP Research Agreement with US Biopharma Co
December 6, 2021
VIRALEZE distribution agreement and launch in Vietnam
December 2, 2021
VIRALEZE registered in Vietnam with launch this week
November 30, 2021
Starpharma : AGM Chairman address and CEO presentation
November 29, 2021
Positive DEP phase 2 interim results in prostate cancer
November 25, 2021
VIRALEZE distribution and supply to Vietnam
October 25, 2021
VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy
October 7, 2021
VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
August 23, 2021
VIRALEZE well tolerated in multiple dose clinical study
August 17, 2021
VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant
July 27, 2021
VIRALEZE UK Update
June 20, 2021
VIRALEZE SPL7013 virucidal against multiple COVID variants
June 17, 2021
VIRALEZE antiviral nasal spray registered for sale in India
June 11, 2021
VIRALEZE SPL7013 highly active in UK variant of coronavirus
June 1, 2021
VIRALEZE launches in Europe
May 6, 2021
Starpharma : VIRALEZE™ now launched by LloydsPharmacy in the UK
March 29, 2021
VIRALEZE to be launched with LloydsPharmacy in the UK
March 24, 2021
DEP HER2-lutetium outperforms in human breast cancer model
March 15, 2021
VIRALEZE antiviral nasal spray registered in Europe
February 22, 2021
Starpharma signs DEP ADC Research Agreement with MSD
February 11, 2021
AZD0466 clinical DEP program global expansion
February 8, 2021
Starpharma : Change in substantial holding
February 2, 2021
VIRALEZE COVID-19 nasal spray study to commence in January
December 22, 2020